2025年中国乳腺癌内生用药行业概览：当“她未说”的疼痛被听见，中国女性健康市场是否按下“加速键”？

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The China breast hyperplasia medication industry is experiencing diversified development, with both traditional Chinese medicine (TCM) and Western medicine collaborating to meet differentiated treatment needs. TCM is favored for its cost-effectiveness and long-term management characteristics, while Western medicine dominates in areas such as hormone regulation and pain control. The industry's growth is primarily driven by increased health awareness among women and the accelerated adoption of early screening and comprehensive health management models under policy guidance. The industry is expected to continue expanding due to policy support, technological innovation, and driven by segmented demand [2][3]. Summary by Sections Industry Overview - Breast hyperplasia is the most common benign breast disease, characterized by symptoms such as breast pain and nodules. The condition arises from abnormal development and degeneration of breast tissue, leading to structural disarray. The clinical manifestations include breast pain, nodular states, or lumps, with some patients experiencing nipple discharge. The pathogenesis is associated with excessive action of hormones such as estradiol, progesterone, and prolactin [3][10][11]. Market Size - The market for breast hyperplasia medication in China is projected to reach 35.98 billion yuan by 2024, with Western medicine accounting for 18.73 billion yuan and TCM for 17.24 billion yuan. By 2029, the market size is expected to grow to 43.27 billion yuan. The demand for TCM is primarily driven by long-term management needs of female patients, while Western medicine is favored for its rapid efficacy in hormone regulation and pain relief [30][31]. Industry Chain Analysis - The upstream analysis indicates that the supply of animal-based medicinal materials is stable, while the prices of root-based materials fluctuate significantly, impacting midstream production. The midstream sector is characterized by a low level of capital participation, with small enterprises relying on unique products to build competitive advantages. The downstream analysis shows a trend towards online sales channels, with a notable shift in treatment preferences among patients [37][41][46]. Competitive Landscape - The competitive landscape of the breast hyperplasia medication industry reveals that TCM products dominate the market, with a significant number of unique products held by non-listed companies. The report highlights that only 31% of manufacturers have a listed company background, indicating a low level of capital involvement in the industry [42][43]. Development Trends - The "Women’s Development Outline" promotes a multi-dimensional approach to the breast hyperplasia medication industry, emphasizing the importance of early screening and comprehensive health management. This policy framework is expected to enhance the accessibility and affordability of breast hyperplasia medications, driving demand for both TCM and Western medicine [34].